Handelsbanken Fonder AB Takes $431,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Handelsbanken Fonder AB purchased a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 11,800 shares of the company’s stock, valued at approximately $431,000.

A number of other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of SpringWorks Therapeutics by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,922,462 shares of the company’s stock valued at $113,807,000 after purchasing an additional 20,651 shares in the last quarter. Fiera Capital Corp grew its position in shares of SpringWorks Therapeutics by 2.9% during the 3rd quarter. Fiera Capital Corp now owns 892,934 shares of the company’s stock valued at $20,645,000 after purchasing an additional 25,510 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of SpringWorks Therapeutics by 16.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,764 shares of the company’s stock valued at $9,797,000 after purchasing an additional 59,138 shares in the last quarter. Walleye Capital LLC grew its position in shares of SpringWorks Therapeutics by 196.8% during the 3rd quarter. Walleye Capital LLC now owns 144,307 shares of the company’s stock valued at $3,336,000 after purchasing an additional 95,694 shares in the last quarter. Finally, TD Asset Management Inc grew its position in shares of SpringWorks Therapeutics by 122.1% during the 3rd quarter. TD Asset Management Inc now owns 138,832 shares of the company’s stock valued at $3,210,000 after purchasing an additional 76,316 shares in the last quarter.

SpringWorks Therapeutics Stock Up 0.3 %

NASDAQ SWTX opened at $46.84 on Thursday. The company has a 50-day simple moving average of $47.40 and a two-hundred day simple moving average of $38.36. SpringWorks Therapeutics, Inc. has a 12-month low of $18.00 and a 12-month high of $53.92. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -9.11 and a beta of 0.83.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The business had revenue of $5.45 million for the quarter, compared to analyst estimates of $1.26 million. During the same period last year, the firm posted ($1.19) EPS. Equities analysts expect that SpringWorks Therapeutics, Inc. will post -4.69 earnings per share for the current fiscal year.

Insider Buying and Selling at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 15,000 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $50.10, for a total transaction of $751,500.00. Following the completion of the sale, the insider now directly owns 45,212 shares in the company, valued at $2,265,121.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 7.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on SWTX shares. Barclays upped their target price on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. upped their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Guggenheim started coverage on shares of SpringWorks Therapeutics in a research report on Monday, February 5th. They issued a “buy” rating and a $75.00 target price for the company. Wedbush upped their target price on shares of SpringWorks Therapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, February 26th. Finally, HC Wainwright upped their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics currently has a consensus rating of “Buy” and an average price target of $68.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.